1. Home
  2. VERU vs TPST Comparison

VERU vs TPST Comparison

Compare VERU & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VERU
  • TPST
  • Stock Information
  • Founded
  • VERU 1971
  • TPST 2011
  • Country
  • VERU United States
  • TPST United States
  • Employees
  • VERU N/A
  • TPST N/A
  • Industry
  • VERU Biotechnology: Pharmaceutical Preparations
  • TPST Biotechnology: Pharmaceutical Preparations
  • Sector
  • VERU Health Care
  • TPST Health Care
  • Exchange
  • VERU Nasdaq
  • TPST Nasdaq
  • Market Cap
  • VERU 54.6M
  • TPST 45.5M
  • IPO Year
  • VERU 1990
  • TPST N/A
  • Fundamental
  • Price
  • VERU $4.29
  • TPST $10.74
  • Analyst Decision
  • VERU Strong Buy
  • TPST Hold
  • Analyst Count
  • VERU 3
  • TPST 3
  • Target Price
  • VERU $33.33
  • TPST $30.00
  • AVG Volume (30 Days)
  • VERU 158.4K
  • TPST 45.5K
  • Earning Date
  • VERU 08-12-2025
  • TPST 11-11-2025
  • Dividend Yield
  • VERU N/A
  • TPST N/A
  • EPS Growth
  • VERU N/A
  • TPST N/A
  • EPS
  • VERU N/A
  • TPST N/A
  • Revenue
  • VERU $16,886,419.00
  • TPST N/A
  • Revenue This Year
  • VERU N/A
  • TPST N/A
  • Revenue Next Year
  • VERU N/A
  • TPST N/A
  • P/E Ratio
  • VERU N/A
  • TPST N/A
  • Revenue Growth
  • VERU 337.24
  • TPST N/A
  • 52 Week Low
  • VERU $2.64
  • TPST $5.35
  • 52 Week High
  • VERU $14.20
  • TPST $20.67
  • Technical
  • Relative Strength Index (RSI)
  • VERU 74.55
  • TPST 57.39
  • Support Level
  • VERU $3.75
  • TPST $8.87
  • Resistance Level
  • VERU $3.99
  • TPST $11.07
  • Average True Range (ATR)
  • VERU 0.24
  • TPST 0.50
  • MACD
  • VERU -0.01
  • TPST 0.07
  • Stochastic Oscillator
  • VERU 94.34
  • TPST 83.58

About VERU Veru Inc.

Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.

About TPST Tempest Therapeutics Inc.

Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.

Share on Social Networks: